Guardant Health's Duplex Sequencing Patent Challenge Rejected by Appeal Board

MT Newswires Live04:47

Guardant Health's (GH) challenge to all 30 claims of a US patent underlying duplex sequencing and owned by the University of Washington was rejected by the Patent Trial and Appeal Board, TwinStrand Biosciences, the patent's exclusive licensee, said Thursday.

The board determined Guardant "failed to establish the unpatentability" of any of the challenged claims, TwinStrand said in a statement.

The patent is one of two at issue in infringement litigation TwinStrand brought against Guardant in the US District Court for the District of Delaware, according to the statement.

The ruling preserved a November 2023 jury verdict that Guardant "willfully infringed" the patent and awarded more than $245.2 million in damages, accrued royalties and interest through May 2026, TwinStrand said.

Guardant was also directed to pay an ongoing royalty of 6% on all covered products and services through March 2033, TwinStrand said.

Guardant did not immediately respond to a request for comment from MT Newswires.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2675053029?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-16 04:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2675053029","market":"sh","top_or_hot":-1,"title":"Guardant Health's Duplex Sequencing Patent Challenge Rejected by Appeal Board","media":"MT Newswires Live","content":"<html><body><p> Guardant Health's (GH) challenge to all 30 claims of a US patent underlying duplex sequencing and owned by the University of Washington was rejected by the Patent Trial and Appeal Board, TwinStrand Biosciences, the patent's exclusive licensee, said Thursday.</p><p>The board determined Guardant \"failed to establish the unpatentability\" of any of the challenged claims, TwinStrand said in a statement.</p><p>The patent is one of two at issue in infringement litigation TwinStrand brought against Guardant in the US District Court for the District of <a href=\"https://laohu8.com/S/VMM\">Delaware</a>, according to the statement.</p><p>The ruling preserved a November 2023 jury verdict that Guardant \"willfully infringed\" the patent and awarded more than $245.2 million in damages, accrued royalties and interest through May 2026, TwinStrand said.</p><p>Guardant was also directed to pay an ongoing royalty of 6% on all covered products and services through March 2033, TwinStrand said.</p><p>Guardant did not immediately respond to a request for comment from MT Newswires.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardant Health's Duplex Sequencing Patent Challenge Rejected by Appeal Board</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardant Health's Duplex Sequencing Patent Challenge Rejected by Appeal Board\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-10-16 04:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Guardant Health's (GH) challenge to all 30 claims of a US patent underlying duplex sequencing and owned by the University of Washington was rejected by the Patent Trial and Appeal Board, TwinStrand Biosciences, the patent's exclusive licensee, said Thursday.</p><p>The board determined Guardant \"failed to establish the unpatentability\" of any of the challenged claims, TwinStrand said in a statement.</p><p>The patent is one of two at issue in infringement litigation TwinStrand brought against Guardant in the US District Court for the District of <a href=\"https://laohu8.com/S/VMM\">Delaware</a>, according to the statement.</p><p>The ruling preserved a November 2023 jury verdict that Guardant \"willfully infringed\" the patent and awarded more than $245.2 million in damages, accrued royalties and interest through May 2026, TwinStrand said.</p><p>Guardant was also directed to pay an ongoing royalty of 6% on all covered products and services through March 2033, TwinStrand said.</p><p>Guardant did not immediately respond to a request for comment from MT Newswires.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LFSC","symbol_name":"F/m Emerald Life Sciences Innovation ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2675053029","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2675053029","pubTimestamp":1792097241,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guardant Health's  challenge to all 30 claims of a US patent underlying duplex sequencing and owned by the University of Washington was rejected by the Patent Trial and Appeal Board, TwinStrand Biosciences, the patent's exclusive licensee, said Thursday.The board determined Guardant \"failed to establish the unpatentability\" of any of the challenged claims, TwinStrand said in a statement.The patent is one of two at issue in infringement litigation TwinStrand brought against Guardant in the US District Court for the District of Delaware, according to the statement.The ruling preserved a November 2023 jury verdict that Guardant \"willfully infringed\" the patent and awarded more than $245.2 million in damages, accrued royalties and interest through May 2026, TwinStrand said.Guardant was also directed to pay an ongoing royalty of 6% on all covered products and services through March 2033, TwinStrand said.Guardant did not immediately respond to a request for comment from MT Newswires.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LFSC":"F/m Emerald Life Sciences Innovation ETF","GNMX":"Corgi Genomics & Precision Medicine ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","USRD":"THEMES US R&D CHAMPIONS ETF","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4551":"寇图资本持仓","EKG":"First Trust Nasdaq Lux Digital Health Solutions ETF","GNOM":"Global X Genomics & Biotechnology ETF","GDOC":"Goldman Sachs Future Health Care Equity ETF","PTH":"Invesco Dorsey Wright Healthcare Momentum ETF","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","HELX":"Franklin Genomic Advancements ETF","BK4588":"碎股","BK4196":"保健护理服务","FFOX":"FUNDX FUTURE FUND OPPORTUNITIES ETF","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","GH":"Guardant Health Inc."},"translate_title":"Guardant Health 的双重测序专利挑战被上诉委员会驳回","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GNMX":0.6,"GNOM":0.6,"LFSC":0.6,"HELX":0.6,"GDOC":0.6,"PTH":0.6,"FFOX":0.6,"GH":1,"USRD":0.7,"EKG":0.6},"content_text":"Guardant Health's (GH) challenge to all 30 claims of a US patent underlying duplex sequencing and owned by the University of Washington was rejected by the Patent Trial and Appeal Board, TwinStrand Biosciences, the patent's exclusive licensee, said Thursday.The board determined Guardant \"failed to establish the unpatentability\" of any of the challenged claims, TwinStrand said in a statement.The patent is one of two at issue in infringement litigation TwinStrand brought against Guardant in the US District Court for the District of Delaware, according to the statement.The ruling preserved a November 2023 jury verdict that Guardant \"willfully infringed\" the patent and awarded more than $245.2 million in damages, accrued royalties and interest through May 2026, TwinStrand said.Guardant was also directed to pay an ongoing royalty of 6% on all covered products and services through March 2033, TwinStrand said.Guardant did not immediately respond to a request for comment from MT Newswires.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2675053029","isCrawlerRequest":true}